MENU
+Compare
APVO
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$3.08
Change
-$0.15 (-4.64%)
Capitalization
9.93M

APVO Aptevo Therapeutics Inc Forecast, Technical & Fundamental Analysis

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer... Show more

Industry: #Biotechnology
APVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for APVO with price predictions
Jun 27, 2025

Momentum Indicator for APVO turns negative, indicating new downward trend

APVO saw its Momentum Indicator move below the 0 level on June 20, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned negative. In of the 102 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for APVO entered a downward trend on June 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where APVO's RSI Oscillator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.362) is normal, around the industry mean (16.366). P/E Ratio (0.001) is within average values for comparable stocks, (58.189). APVO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.247).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
APVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

APVO is expected to report earnings to fall 90.09% to -43 cents per share on May 09

Aptevo Therapeutics Inc APVO Stock Earnings Reports
Q1'24
Est.
$-0.44
Q1'25
Missed
by $4.11
Q4'23
Missed
by $11.52
Q3'23
Missed
by $21.36
Q2'23
Missed
by $53.00
The last earnings report on May 15 showed earnings per share of -438 cents, missing the estimate of -28 cents. With 308.18K shares outstanding, the current market capitalization sits at 9.93M.
A.I. Advisor
published General Information

General Information

a provider of immunology and cancer research services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2401 4th Avenue
Phone
+1 206 838-0500
Employees
40
Web
https://www.aptevotherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NMR6.600.28
+4.43%
Nomura Holdings
CRGO2.520.10
+4.13%
Freightos Limited
AIN69.510.33
+0.48%
Albany International Corp
TGB3.05-0.10
-3.17%
Taseko Mines Limited
POAI0.83-0.03
-3.50%
Predictive Oncology

APVO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, APVO has been loosely correlated with ENLV. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if APVO jumps, then ENLV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APVO
1D Price
Change %
APVO100%
-4.64%
ENLV - APVO
36%
Loosely correlated
-0.83%
GNPX - APVO
28%
Poorly correlated
-4.70%
KROS - APVO
28%
Poorly correlated
-0.15%
IBO - APVO
27%
Poorly correlated
-18.26%
IMRX - APVO
26%
Poorly correlated
+10.66%
More